nach oben

Journal of Neural Transmission

Erschienen in:

01.02.2016 | Neurology and Preclinical Neurological Studies - Review Article

Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview

verfasst von: Cristina Carvalho, Sónia C. Correia, George Perry, Rudy J. Castellani, Paula I. Moreira

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Multiple lines of evidence suggest that vascular alterations contribute to Alzheimer’s disease (AD) pathogenesis. It is also well established that mitochondrial abnormalities occur early in course of AD. Here, we give an overview of the vascular and mitochondrial abnormalities occurring in AD, including mitochondrial alterations in vascular endothelial cells within the brain, which is emerging as a common feature that bridges cerebral vasculature and mitochondrial metabolism.

Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA et al (2002) Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease. Neurobiol Aging 23:371–376CrossRefPubMed

Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695–703CrossRefPubMed

Carrano A, Hoozemans JJ, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJ (2012) Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 10:329–331CrossRefPubMed

Carvalho C, Correia SC, Santos RX, Cardoso S, Moreira PI, Clark TA et al (2009) Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J Bioenerg Biomembr 41:433–440PubMedCentralCrossRefPubMed

Carvalho C, Santos MS, Baldeiras I, Oliveira CR, Seiça R, Moreira PI (2010) Chronic hypoxia potentiates age-related oxidative imbalance in brain vessels and synaptosomes. Curr Neurovasc Res 7:288–300CrossRefPubMed

Castellani RJ, Smith MA, Perry G, Friedland RP (2004) Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer’s disease pathogenesis. Neurobiol Dis 25:599–602

Chang HC, Chen TG, Tai YT, Chen TL, Chiu WT, Chen RM (2011) Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab 3:842–854CrossRef

Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ (2003) Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 278:36027–36031CrossRefPubMed

Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z et al (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324:102–105PubMedCentralCrossRefPubMed

Chou JL, Shenoy DV, Thomas N, Choudhary PK, Laferla FM, Goodman SR et al (2011) Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer’s disease. J Proteomics 74:466–479CrossRefPubMed

Claudio L (1996) Ultrastructural features of the blood–brain barrier in biopsy tissue from Alzheimer’s disease patients. Acta Neuropathol 91:6–14CrossRefPubMed

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2014) Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321CrossRefPubMed

Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM et al (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med 14:1097–1105PubMedCentralCrossRefPubMed

Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S et al (2009) The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 108:1045–1056CrossRefPubMed

Hamdheydari L, Christov A, Ottman T, Hensley K, Grammas P (2003) Oxidized LDLs affect nitric oxide and radical generation in brain endothelial cells. Biochem Biophys Res Comm 311:486–490CrossRefPubMed

Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS et al (2001) Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 21:3017–3023PubMed

Huang HM, Ou HC, Xu H, Chen HL, Fowler C, Gibson GE (2003) Inhibition of alpha ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J Neurosci Res 74:309–317CrossRefPubMed

Humpel C (2011) Chronic mild cerebrovascular dysfunction as a cause for Alzheimer’s disease? Exp Gerontol 46:225–232PubMedCentralCrossRefPubMed

Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4:147CrossRef

Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L et al (2014) Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci 34:16180–16193PubMedCentralCrossRefPubMed

Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ et al (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234:851–859PubMedCentralCrossRefPubMed

Khandelwal PJ, Herman AM, Hoe HS, Rebeck GW, Moussa CE (2011) Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum Mol Genet 20:2091–2102PubMedCentralCrossRefPubMed

Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ et al (1992) Brain cytochrome oxidase in Alzheimer’s disease. J Neurochem 59:776–779CrossRefPubMed

Kolev K, Skopál J, Simon L, Csonka E, Machovich R, Nagy Z (2003) Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NF-kappaB as a signal transducer. Thromb Haemost 90:528–537PubMed

Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D et al (2014) Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76:845–861PubMedCentralCrossRefPubMed

Kushnareva Y, Murphy AN, Andreyev A (2002) Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation–reduction state. Biochem J 368:545–553PubMedCentralCrossRefPubMed

Leuner K, Schütt T, Kurz C, Eckert SH, Schiller C, Occhipinti A et al (2012) Mitochondria-derived ROS lead to enhanced amyloid beta formation. Antioxid Redox Signal 16:1421–1433PubMedCentralCrossRefPubMed

Moreira PI (2012) Alzheimer’s disease and diabetes: an integrative view of the role of mitochondria, oxidative stress and insulin. J Alzheimers Dis 30:S199–S215PubMed

Moreira PI, Santos MS, Moreno A, Oliveira C (2001) Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 21:789–800CrossRefPubMed

Moreira PI, Santos MS, Moreno A, Rego AC, Oliveira C (2002) Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 69:257–267CrossRefPubMed

Moreira PI, Santos MS, Sena C, Nunes E, Seiça R, Oliveira CR (2005a) CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 196:112–119CrossRefPubMed

Moreira PI, Santos MS, Sena C, Seiça R, Oliveira CR (2005b) Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol Dis 18:628–637CrossRefPubMed

Moreira PI, Santos MS, Oliveira CR (2007a) Alzheimer’s disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 9:1621–1630CrossRefPubMed

Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M et al (2007b) Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol 66:525–532CrossRefPubMed

Murray IV, Proza JF, Sohrabji F, Lawler JM (2011) Vascular and metabolic dysfunction in Alzheimer’s disease: a review. Exp Biol Med (Maywood) 236:772–782CrossRef

Nag S (2002) The blood-brain barrier and cerebral angiogenesis: lessons from the cold-injury model. Trends Mol Med 8:38–44CrossRefPubMed

Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759–767CrossRefPubMed

Panza F et al (2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Rev Neurother 14:973–986CrossRefPubMed

Parker WD Jr, Mahr NJ, Filley CM, Parks JK, Hughes D, Young DA et al (1994) et al. Reduced platelet cytochrome c oxidase activity in Alzheimer’s disease. Neurology 44:1086–1090CrossRefPubMed

Pu PB, Lu J, Moochhala S (2009) Involvement of ROS in BBB dysfunction. Free Radic Res 43:348–364CrossRef

Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344CrossRefPubMed

Resende R, Moreira PI, Proença T, Deshpande A, Busciglio J, Pereira C et al (2008) Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44:2051–2057CrossRefPubMed

Rombouts SA, Goekoop R, Stam CJ, Barkhof F, Scheltens P (2005) Delayed rather than decreased BOLD response as a marker for early Alzheimer’s disease. Neuroimage 26:1078–1085CrossRefPubMed

Roy S, Rauk A (2005) Alzheimer’s disease and the ‘ABSENT’ hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity. Med Hypotheses 65:123–137CrossRefPubMed

Sabayan B, Jansen S, Oleksik AM, van Osch MJ, van Buchem MA, van Vliet P et al (2012) Cerebrovascular hemodynamics in Alzheimer’s disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev 11:271–277CrossRefPubMed

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333PubMedCentralCrossRefPubMed

Sun X, He G, Qing H, Zhou W, Dobie F, Cai F et al (2006) Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 103:18727–18732PubMedCentralCrossRefPubMed

Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN et al (2006) Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment. Mitochondrion 6:323–330PubMedCentralCrossRefPubMed

Wang X, Su B, Fujioka H, Zhu X (2008a) Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol 173:470–482PubMedCentralCrossRefPubMed

Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y et al (2008b) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105:19318–19323PubMedCentralCrossRefPubMed

Xu J, Chen S, Ku G, Ahmed SH, Xu J, Chen H et al (2001) Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab 21:702–710CrossRefPubMed

Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 106:14670–14675PubMedCentralCrossRefPubMed

Titel: Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview
verfasst von: Cristina Carvalho
Sónia C. Correia
George Perry
Rudy J. Castellani
Paula I. Moreira
Publikationsdatum: 01.02.2016
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-015-1367-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Mitochondrial mechanisms of redox cycling agents implicated in Parkinson’s disease

Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression

Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease

Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets